Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + anlotinib + TP first-line treatment for unresectable locally advanced or metastatic esophageal squamous cell carcinoma
ChiCTR2300079301Phase 2Recruiting
- Sponsor
- Qingdao Municipal Hospital
- Start
- Dec 2023
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab, anlotinib, liposomal paclitaxel and cisplatin in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Qingdao Municipal Hospital. Primary endpoint: Objective response rate. Started Dec 2023; status: recruiting.
02
Drugs
sintilimabanlotinibliposomal paclitaxelcisplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2300079301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300079301.